Rhumbline Advisers decreased its stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART – Free Report) by 1.0% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 234,055 shares of the life sciences company’s stock after selling 2,342 shares during the quarter. Rhumbline Advisers owned about 0.29% of Integra LifeSciences worth $13,437,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Commonwealth Equity Services LLC boosted its stake in shares of Integra LifeSciences by 3.4% during the 1st quarter. Commonwealth Equity Services LLC now owns 7,916 shares of the life sciences company’s stock worth $454,000 after acquiring an additional 263 shares during the period. Vanguard Personalized Indexing Management LLC bought a new position in shares of Integra LifeSciences during the 1st quarter worth approximately $409,000. Zions Bancorporation N.A. boosted its stake in shares of Integra LifeSciences by 15.8% during the 1st quarter. Zions Bancorporation N.A. now owns 19,665 shares of the life sciences company’s stock worth $1,129,000 after acquiring an additional 2,687 shares during the period. South Dakota Investment Council boosted its stake in shares of Integra LifeSciences by 15.9% during the 1st quarter. South Dakota Investment Council now owns 39,856 shares of the life sciences company’s stock worth $2,288,000 after acquiring an additional 5,460 shares during the period. Finally, Bessemer Group Inc. boosted its stake in shares of Integra LifeSciences by 21.7% during the 1st quarter. Bessemer Group Inc. now owns 11,986 shares of the life sciences company’s stock worth $688,000 after acquiring an additional 2,134 shares during the period. Institutional investors and hedge funds own 84.13% of the company’s stock.
Analysts Set New Price Targets
Several brokerages have recently commented on IART. Argus downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a research note on Thursday, June 8th. JMP Securities reduced their price target on Integra LifeSciences from $65.00 to $60.00 and set an “outperform” rating for the company in a research note on Friday, July 28th. Citigroup downgraded Integra LifeSciences from a “neutral” rating to a “sell” rating and reduced their price target for the company from $59.00 to $39.00 in a research note on Tuesday, May 23rd. TheStreet downgraded Integra LifeSciences from a “b-” rating to a “c+” rating in a research note on Monday, May 22nd. Finally, 22nd Century Group restated a “downgrade” rating on shares of Integra LifeSciences in a research note on Tuesday, May 23rd. Three analysts have rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $47.29.
Integra LifeSciences Stock Performance
NASDAQ:IART opened at $42.76 on Friday. The stock has a fifty day moving average price of $43.04 and a 200-day moving average price of $48.27. The company has a market cap of $3.48 billion, a price-to-earnings ratio of 27.24, a PEG ratio of 1.71 and a beta of 1.19. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.85 and a current ratio of 2.78. Integra LifeSciences Holdings Co. has a fifty-two week low of $37.36 and a fifty-two week high of $60.69.
Integra LifeSciences (NASDAQ:IART – Get Free Report) last released its earnings results on Wednesday, July 26th. The life sciences company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.14. The firm had revenue of $381.30 million during the quarter, compared to the consensus estimate of $388.79 million. Integra LifeSciences had a return on equity of 15.60% and a net margin of 8.49%. The company’s revenue was down 4.1% compared to the same quarter last year. During the same period in the prior year, the company posted $0.82 EPS. As a group, equities analysts anticipate that Integra LifeSciences Holdings Co. will post 3.14 EPS for the current fiscal year.
Integra LifeSciences Company Profile
Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology.
- Five stocks we like better than Integra LifeSciences
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- Your Comprehensive Guide to Investing in Bank Stocks
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
- Investing in Construction Stocks
- 5 Critical Takeaways From MongoDB’s Q2 Results for AI Investors
Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.